Myricx Bio
London
About Myricx Bio
Myricx Bio is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyl transferase (NMT), primarily focusing on oncology and exploring potential applications across other diseases. NMT is an enzyme that modifies key proteins for cancer cell survival with specific lipids. Myricx Bio is developing a pipeline of ADCs using its NMT inhibitor (NMTi) payload platform to address critical unmet needs in oncology. It shows excellent preclinical efficacy and safety across various solid tumor antigens and cancer cell types.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $121.3M
- Funding stage: Early Stage Venture
- Last round: Series A (Jul 2024)
- Website: myricxbio.com
Industries & Categories
Biotechnology, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/myricx-bio-57857 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.